Germany Expands Travel Vaccine Access

With international travel expected to accelerate over the next few years, more Germans will soon have access to innovative travel vaccines based on a new distribution agreement.

Valneva SE announced today an exclusive three-year agreement with CSL Seqirus for the marketing and distribution of Valneva’s three proprietary vaccines in Germany.

Under the terms of the agreement announced on June 26, 2025, CSL Seqirus will begin commercializing Valneva’s single-dose chikungunya vaccine, IXCHIQ®, starting in July 2025.

Additionally, they will market Valneva’s Japanese Encephalitis vaccine, IXIARO®, and the cholera/ETEC vaccine, DUKORAL®, from January 2026.

Dipal Patel, Chief Commercial Officer at Valneva, stated in a press release, “We are excited to partner with CSL Seqirus to enhance our commercial sales in Germany. CSL’s strong presence in the German market will ensure the efficient distribution of our vaccines in Europe’s largest travel vaccine market, complementing our in-house commercial infrastructure focused on other key markets in Europe.”

This new agreement with CSL Seqirus includes minimum annual purchasing quantities and standard termination clauses based on changes in control and non-performance. Valneva expects product sales to grow to €170-180 million in 2025, resulting in positive cash flow for its overall commercial business.

These Valneva vaccines are also available in numerous countries, including the United States.

The way U.S. citizens travel to Germany is expected to change in 2026. There will be an additional requirement for all non-EU visa-exempt visitors, including Americans.

American tourists and business travelers can still spend up to 90 days in Germany visa-free; however, the European Travel Information and Authorization System will be required starting in 2026.

To alert international travelers, the U.S. Department of State issued a Security Alert on the U.S. Embassy & Consulates in Germany website. As of June 23, 2025, the State Department advises U.S. citizens worldwide to exercise increased caution.